XOMA Royalty Corporation Overview
Pro stress-test →XOMA Royalty Corporation operates as a biotech royalty aggregator with a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company provides non-dilutive, non-recourse funding to biotech partners in exchange for future royalty streams and milestone payments.
Strategic Profile
Pro stress-test →XOMA transitioned from a traditional biopharmaceutical developer to a specialized biotechnology royalty aggregator in July 2024. The company boasts an expansive and continuously growing portfolio of over 120 assets, with extensive diversification serving as a key strength in mitigating the inherent risks of biotech investments. Management continues to add to the diversified portfolio through disciplined capital deployment and creative financial structures.
Competitive Landscape
Pro stress-test →XOMA focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential, and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. The pure-play royalty aggregator model is relatively specialized within biotech; primary indirect competitors are traditional venture capitalists and pharma companies licensing internally. A significant portion of XOMA assets are partnered with large-cap pharmaceutical companies.
Industry Context
XOMA Royalty Corporation operates in Biotechnology / Biotech Royalty Aggregation.
Key facts
Founded: 1981 · Headquarters: Emeryville, California · Revenue: $13.4M · Market cap: $333M